Published in J Am Chem Soc on November 15, 2010
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv (2012) 0.97
Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Adv Funct Mater (2014) 0.95
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics (2013) 0.94
Acid-degradable polymer-caged lipoplex (PCL) platform for siRNA delivery: facile cellular triggered release of siRNA. J Am Chem Soc (2013) 0.86
Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.85
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine (2015) 0.82
Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev (2015) 0.80
Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. J Pharm Sci (2016) 0.80
Triggered release of pharmacophores from [Ni(HAsO₃)]-loaded polymer-caged nanobin enhances pro-apoptotic activity: a combined experimental and theoretical study. ACS Nano (2011) 0.78
Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer. Int J Nanomedicine (2017) 0.75
Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. Sci Rep (2016) 0.75
Advances in drug delivery system for platinum agents based combination therapy. Cancer Biol Med (2015) 0.75
DNA Polyplexes as Combinatory Drug Carriers of Doxorubicin and Cisplatin: An in Vitro Study. Mol Pharm (2015) 0.75
Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes. Macromolecules (2013) 0.75
Polydopamine Nanoparticles for Combined Chemo- and Photothermal Cancer Therapy. Nanomaterials (Basel) (2017) 0.75
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 9.28
What is synergy? Pharmacol Rev (1989) 6.08
Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res (1989) 5.62
Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry (1998) 5.30
Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer (2009) 5.06
Micellar nanocontainers distribute to defined cytoplasmic organelles. Science (2003) 4.37
Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol (2009) 4.30
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Direct cellular responses to platinum-induced DNA damage. Chem Rev (2007) 3.42
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc (2007) 2.82
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res (2004) 2.37
Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol (2004) 2.03
Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry (1998) 1.96
Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano (2010) 1.82
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol (2006) 1.44
A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf (2001) 1.33
Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med (2002) 1.32
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol (2003) 1.19
"Clickable" polymer-caged nanobins as a modular drug delivery platform. J Am Chem Soc (2009) 1.18
Polymer-caged lipsomes: a pH-responsive delivery system with high stability. J Am Chem Soc (2007) 1.16
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res (2010) 1.12
Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol (2006) 1.12
Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res (2006) 1.10
Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol (2001) 1.06
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed Engl (2009) 1.04
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer (2001) 1.02
Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs (1999) 1.00
Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res (2001) 1.00
Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res (1997) 0.95
Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol (2000) 0.95
Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res (1993) 0.87
Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. Cancer Chemother Pharmacol (2007) 0.83
Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer (2009) 0.82
Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol Cancer Ther (2006) 0.82
Four-year analysis of platinum and anthracycline combination for ovarian cancer. Oncology (1989) 0.82
DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res (1995) 0.79
Graphene-based composite materials. Nature (2006) 9.90
Preparation and characterization of graphene oxide paper. Nature (2007) 6.28
Transition metal speciation in the cell: insights from the chemistry of metal ion receptors. Science (2003) 5.12
Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A (2006) 3.30
Molecular basis of metal-ion selectivity and zeptomolar sensitivity by CueR. Science (2003) 3.08
Metal-organic framework materials as catalysts. Chem Soc Rev (2009) 2.96
Oxygen-induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS. EMBO J (2004) 2.55
Activation of superoxide dismutases: putting the metal to the pedal. Biochim Biophys Acta (2006) 2.33
Cu(I) recognition via cation-pi and methionine interactions in CusF. Nat Chem Biol (2007) 2.28
Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice. Proc Natl Acad Sci U S A (2006) 2.22
Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. J Biol Chem (2005) 2.19
Directed assembly of transition-metal-coordinated molecular loops and squares from salen-type components. Examples of metalation-controlled structural conversion. J Am Chem Soc (2004) 2.18
De novo synthesis of a metal-organic framework material featuring ultrahigh surface area and gas storage capacities. Nat Chem (2010) 2.11
The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J Biol Chem (2004) 1.97
Graphene oxide, highly reduced graphene oxide, and graphene: versatile building blocks for carbon-based materials. Small (2010) 1.83
Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria. J Biol Chem (2003) 1.83
Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano (2010) 1.82
Metallochaperones and metal-transporting ATPases: a comparative analysis of sequences and structures. Genome Res (2002) 1.80
Zinc availability regulates exit from meiosis in maturing mammalian oocytes. Nat Chem Biol (2010) 1.76
Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. J Biol Chem (2008) 1.69
Emission ratiometric imaging of intracellular zinc: design of a benzoxazole fluorescent sensor and its application in two-photon microscopy. J Am Chem Soc (2004) 1.66
Fluxes in "free" and total zinc are essential for progression of intraerythrocytic stages of Plasmodium falciparum. Chem Biol (2012) 1.59
A place for thioether chemistry in cellular copper ion recognition and trafficking. Nat Chem Biol (2008) 1.46
Oxygen and the copper chaperone CCS regulate posttranslational activation of Cu,Zn superoxide dismutase. Proc Natl Acad Sci U S A (2004) 1.45
Zinc sparks are triggered by fertilization and facilitate cell cycle resumption in mammalian eggs. ACS Chem Biol (2011) 1.37
Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis. Antioxid Redox Signal (2006) 1.36
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther (2009) 1.27
Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc (2006) 1.27
A metal-organic framework material that functions as an enantioselective catalyst for olefin epoxidation. Chem Commun (Camb) (2006) 1.22
Metal-organic framework materials with ultrahigh surface areas: is the sky the limit? J Am Chem Soc (2012) 1.21
Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science (2009) 1.21
"Clickable" polymer-caged nanobins as a modular drug delivery platform. J Am Chem Soc (2009) 1.18
Polymer-caged lipsomes: a pH-responsive delivery system with high stability. J Am Chem Soc (2007) 1.16
Graphene-silica composite thin films as transparent conductors. Nano Lett (2007) 1.16
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res (2010) 1.12
Signal amplification and detection via a supramolecular allosteric catalyst. J Am Chem Soc (2005) 1.12
The PcoC copper resistance protein coordinates Cu(I) via novel S-methionine interactions. J Am Chem Soc (2003) 1.12
Zinc requirement during meiosis I-meiosis II transition in mouse oocytes is independent of the MOS-MAPK pathway. Biol Reprod (2010) 1.10
A supramolecular approach to an allosteric catalyst. J Am Chem Soc (2003) 1.10
Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des (2011) 1.05
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed Engl (2009) 1.04
A zinc-dependent mechanism regulates meiotic progression in mammalian oocytes. Biol Reprod (2012) 1.04
Spectroscopy of Cu(II)-PcoC and the multicopper oxidase function of PcoA, two essential components of Escherichia coli pco copper resistance operon. Biochemistry (2002) 1.02
A new zinc-protein coordination site in intracellular metal trafficking: solution structure of the Apo and Zn(II) forms of ZntA(46-118). J Mol Biol (2002) 0.98
Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release. Angew Chem Int Ed Engl (2010) 0.98
An atypical linear Cu(I)-S2 center constitutes the high-affinity metal-sensing site in the CueR metalloregulatory protein. J Am Chem Soc (2003) 0.98
Vapor-phase metalation by atomic layer deposition in a metal-organic framework. J Am Chem Soc (2013) 0.96
Allosterically regulated supramolecular catalysis of acyl transfer reactions for signal amplification and detection of small molecules. J Am Chem Soc (2007) 0.96
Role of CTR4 in the Virulence of Cryptococcus neoformans. MBio (2012) 0.96
High-density doxorubicin-conjugated polymeric nanoparticles via ring-opening metathesis polymerization. Chem Commun (Camb) (2005) 0.95
Crystal structure and dimerization equilibria of PcoC, a methionine-rich copper resistance protein from Escherichia coli. J Biol Inorg Chem (2002) 0.95
Successful stabilization of graphene oxide in electrolyte solutions: enhancement of biofunctionalization and cellular uptake. ACS Nano (2011) 0.93
Light-harvesting metal-organic frameworks (MOFs): efficient strut-to-strut energy transfer in bodipy and porphyrin-based MOFs. J Am Chem Soc (2011) 0.93
A catalytically active, permanently microporous MOF with metalloporphyrin struts. J Am Chem Soc (2009) 0.93
Liposomal spherical nucleic acids. J Am Chem Soc (2014) 0.91
Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic beta-cell function. J Endocrinol (2010) 0.90
Crumpled graphene nanosheets as highly effective barrier property enhancers. Adv Mater (2010) 0.89
Growth of narrowly dispersed porphyrin nanowires and their hierarchical assembly into macroscopic columns. J Am Chem Soc (2008) 0.89
Supramolecular allosteric cofacial porphyrin complexes. J Am Chem Soc (2006) 0.89
Zinc maintains prophase I arrest in mouse oocytes through regulation of the MOS-MAPK pathway. Biol Reprod (2012) 0.89
A computational study of the mechanism of the [(salen)Cr + DMAP]-catalyzed formation of cyclic carbonates from CO2 and epoxide. Chem Commun (Camb) (2014) 0.88
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One (2013) 0.88
Size control of arsenic trioxide nanocrystals grown in nanowells. J Am Chem Soc (2009) 0.88
Sharp melting transitions in DNA hybrids without aggregate dissolution: proof of neighboring-duplex cooperativity. J Am Chem Soc (2007) 0.87
Dendronized protein polymers: synthesis and self-assembly of monodisperse cylindrical macromolecules. J Am Chem Soc (2004) 0.87
Sharp melting of polymer-DNA hybrids: an associative phase separation approach. J Phys Chem B (2007) 0.86
Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther (2013) 0.86
Tuning the mechanical properties of graphene oxide paper and its associated polymer nanocomposites by controlling cooperative intersheet hydrogen bonding. ACS Nano (2012) 0.86
Acid-degradable polymer-caged lipoplex (PCL) platform for siRNA delivery: facile cellular triggered release of siRNA. J Am Chem Soc (2013) 0.86
Chiral (salen)Co(III) catalyst for the synthesis of cyclic carbonates. Chem Commun (Camb) (2004) 0.85
Retracted Cooperative melting in caged dimers of rigid small molecule-DNA hybrids. J Am Chem Soc (2008) 0.85
Post-synthesis modification of a metal-organic framework to form metallosalen-containing MOF materials. J Am Chem Soc (2011) 0.85
Accumulation of cadmium in insulin-producing β cells. Islets (2012) 0.85
Catalytic, three-component assembly reaction for the synthesis of pyrrolidines. Org Lett (2003) 0.85
Active-site-accessible, porphyrinic metal-organic framework materials. J Am Chem Soc (2011) 0.85
Building conjugated organic structures on Si(111) surfaces via microwave-assisted Sonogashira coupling. Langmuir (2010) 0.84
Selective bifunctional modification of a non-catenated metal-organic framework material via "click" chemistry. J Am Chem Soc (2009) 0.83
(Salen)tin complexes: syntheses, characterization, crystal structures, and catalytic activity in the formation of propylene carbonate from CO(2) and propylene oxide. Inorg Chem (2004) 0.83
Bio-inspired borate cross-linking in ultra-stiff graphene oxide thin films. Adv Mater (2011) 0.83
Supramolecular porphyrinic prisms: coordinative assembly and solution phase X-ray structural characterization. Chem Commun (Camb) (2006) 0.83
Zinc, insulin, and the liver: a ménage à trois. J Clin Invest (2013) 0.82
Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes. Inorg Chem (2013) 0.82
Cavity-tailored, self-sorting supramolecular catalytic boxes for selective oxidation. J Am Chem Soc (2008) 0.82
Enhanced catalytic activity through the tuning of micropore environment and supercritical CO2 processing: Al(porphyrin)-based porous organic polymers for the degradation of a nerve agent simulant. J Am Chem Soc (2013) 0.81
High propene/propane selectivity in isostructural metal-organic frameworks with high densities of open metal sites. Angew Chem Int Ed Engl (2012) 0.81
Hollow porphyrin prisms: modular formation of permanent, torsionally rigid nanostructures via templated olefin metathesis. Chem Commun (Camb) (2008) 0.81
Designing higher surface area metal-organic frameworks: are triple bonds better than phenyls? J Am Chem Soc (2012) 0.80
A mechanistic investigation of the asymmetric Meerwein-Schmidt-Ponndorf-Verley reduction catalyzed by BINOL/AlMe(3)-structure, kinetics, and enantioselectivity. J Org Chem (2007) 0.80
Efficient and selective Al-catalyzed alcohol oxidation via Oppenauer chemistry. J Am Chem Soc (2006) 0.80
Cooperative melting in caged dimers with only two DNA duplexes. J Am Chem Soc (2010) 0.80
Comparative X-ray standing wave analysis of metal-phosphonate multilayer films of dodecane and porphyrin molecular square. J Phys Chem B (2005) 0.80
A copper hyperaccumulation phenotype correlates with pathogenesis in Cryptococcus neoformans. Metallomics (2013) 0.79
Selective surface and near-surface modification of a noncatenated, catalytically active metal-organic framework material based on Mn(salen) struts. Inorg Chem (2011) 0.79
Axial ligand effects: utilization of chiral sulfoxide additives for the induction of asymmetry in (salen)ruthenium(II) olefin cyclopropanation catalysts. Angew Chem Int Ed Engl (2005) 0.79
Improved anti-proliferative effect of doxorubicin-containing polymer nanoparticles upon surface modification with cationic groups. J Mater Chem (2012) 0.79
Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes. Angew Chem Int Ed Engl (2013) 0.78